Leukotrienes may mediate bronchoconstriction in asthma. Cysteinyl leukotriene production rises in vivo after allergen challenge, but few reports describe leukotriene concentrations in clinical asthma or in children. Using high performance liquid chromatography/radioimmunoassay, plasma and urinary leukotrienes in asthmatic children (aged 5-10 years) were measured during an acute exacerbation (peak expiratory flow (PEF) <65%, n= 10) and one month later (PEF 74-169%, n=9), and in non-atopic normal children (aged 1-3-13-2 years). In the asthmatics, geometric mean (95% confidence interval) plasma leukotriene B4 (LTB4) was 746 pg/ml (398 to 1403) acutely and 1026 pg/ml (662 to 1593) in remission, compared with 369 pg/ml (167 to 728) in the normal children (n= 14). Plasma cysteinyl leukotrienes were low or undetectable, but urinary leukotriene E4 (LTE4) was higher in the asthmatics during an acute episode (210 pmoUnmmol creatinine, 101 to 454) and at follow up (179 pmonnmmol, 110 to 293), compared with the normal children (98 pmonlmmol, 81 to 118, n=41). This persistent increase in plasma LTB4 and urinary LTE4 concentrations one month after a severe asthmatic episode suggests leukotriene production is related to chronic inflammation rather than to acute bronchoconstriction. (Arch Dis Child 1995; 73: 221-225) 
It is increasingly accepted that Among these products are the lipid mediators cysteinyl leukotrienes (leukotriene C4 (LTC4), leukotriene D4 (LTD4), and leukotriene E4 (LTE4)), which abundant evidence implicates in airflow obstruction in asthma.2 They are potent inducers of bronchoconstriction,3 mucus hypersecretion,4 and airway oedema.5 LTE4 concentrations, used as a marker of whole body cysteinyl leukotriene production, rise after challenge of asthmatics with inhaled allergen6 and exercise. 7 Cysteinyl leukotriene receptor antagonists inhibit both early and late bronchoconstrictor responses to allergen and block the associated increase in bronchial responsiveness,8 and they improve lung function and reduce symptoms in chronic asthma. 9 In contrast, the possible role of leukotriene B4 (LTB4) in asthma is unclear. However, it is the most potent lipid chemotaxin known for neutrophils, which are implicated in sudden onset fatal asthma'0 and in nocturnal asthma," and also chemoattracts monocytes, lymphocytes, and eosinophils.12 In vitro, LTB4 induces Th2 lymphocyte production of IL-5,'3 which may promote eosinophilia in asthma and atopy, and augments the stimulatory effects of IL-4 on immunoglobulin E production by B lymphocytes. 14 LTB4 can be generated by a range of cells within the lung, including mast cells and macrophages, '5 16 and has been implicated in neutrophil infiltration after segmental allergen challenge in the human lung. 17 LTB4 has been reliably detected in the bronchoalveolar lavage fluid of asthmatic subjects. '8 Previous work by our group has shown a two to fivefold increased capacity for LTB4 and LTC4 generation in vitro by the peripheral blood polymorphonuclear leucocytes of stable atopic asthmatic subjects stimulated by calcium ionophore or formyl-met-leu-phe. 19 20 In vivo, such an exaggerated leukotriene synthetic response to immunological stimulation within the asthmatic lung might contribute significantly to bronchoconstriction, chronic inflammation, and bronchial hyperresponsiveness. 21 We aimed therefore to use combined high performance liquid chromatography (HPLC)/ radioimmunoassay techniques to assay LTB4, LTC4, LTD4, and LTE4 in the plasma, and LTE4 in the urine, of asthmatic children admitted to hospital with an acute exacerbation, and at follow up at least one month later after clinical improvement. Attempts were made to reduce the possible confounding effects of anti-inflammatory medication, and concentrations were compared with those in a control group of normal children with no personal or family history of allergic disease.
Subjects and methods

CLINICAL CHARACTERISTICS OF SUBJECTS
Permission for the study (No B81/89) was obtained from the ethics committee of King's College Hospital. Ten children with acute asthma (aged 5-10 years) were admitted with acute dyspnoea and wheezing. Peak expiratory flow (PEF) was <65% of predicted, with nine out of 10 having PEF <40% predicted. All had taken inhaled ,2-agonists, but only one out of 10 was on inhaled corticosteroids, two were receiving sodium cromoglycate, and none were receiving theophyllines. All had a close family history of atopy, and skin prick tests were positive (two or more allergens) in four subjects tested. Blood and urine samples were taken before treatment with systemic steroids was begun.
Nine of the 10 asthmatic children provided blood and urine samples at follow up at least one month after the acute episode. All were well with PEF 74-169% of predicted. Although all had received systemic corticosteroid treatment for five days after admission, none had received systemic steroids for at least 25 days preceding the follow up visit. Only two out of nine children were receiving inhaled corticosteroids, and none had received theophyllines for at least 14 days.
Normal children (aged 1 3-13-2 years) with negative personal and family histories of atopy provided blood (n=14) or urine (n=41) as controls. All were healthy with no history of chronic respiratory disease and none were receiving medication. SAMPLE 
COLLECTION
Blood (10 ml) was taken into a heparinised syringe containing the 5-lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA; 50 ,uM; Sigma) and the cysteinyl leukotriene bioconversion blockers L-serine-borate (30 mM) and L-cysteine (10 mM), to 1) were above detection limits in all subjects except one normal. Geometric mean (95% CI) plasma LTB4 concentrations were 746 pg/ml (398 to 1403) in the asthmatic subjects during the acute exacerbation (n= 10), twice that in the normal subjects (geometric mean 369 pg/ml, 95% CI 167 to 728; n= 14); however, this did not reach statistical significance (p=0097). Geometric mean plasma LTB4 concentrations rose further at follow up to 1026 pg/ml (662 to 1593; n=9), which was significantly higher than in the normal subjects (p=0-012).
CYSTEINYL LEUKOTRIENE CONCENTRATIONS IN PLASMA
Plasma concentrations of LTC4 and LTD4 were below detection limits (<50 pg/ml) in all asthmatic patients studied (n=6) both acutely and at follow up, and in all normal subjects studied (n=6; data not shown).
Plasma concentration of LTE4, however, were detected in 11 out of 14 normal subjects, and in all asthmatic patients both acutely and in remission (fig 2) . In the asthmatics, geometric mean (95% CI) plasma LTE4 concentrations were 314 pg/ml (191 to 517) during the acute exacerbation (n= 10) and 348 pg/ml (189 to 643) at follow up (n=9). Neither of these concentrations was significantly greater (p>0.3) than the plasma LTE4 concentration in normal subjects (geometric mean 232 pg/ml, 95% CI: 132 to 406; n=14). The high variability in the normal plasma LTE4 concentrations means that the power of the study to detect small group differences is relatively low. However, an enhancement of the same magnitude as that observed with LTB4 (2.9-fold), would be detectable in plasma LTI trations with a power of approximE the probability of a significant type therefore low.
URINARY LTE4 CONCENTRATIONS
In contrast to the plasma LTE4 significant increase in urinary LTE4 ent in the asthmatic subjects (fig 3) . mean (95% CI) urine LTE4 concent 219 pmollmmol creatinine (101 to 4 the acute exacerbation (n=10) pmol/mmol creatinine (110 to 293, up (n=9), both significantly higher t normal children (geometric mean < CI: 81 to 118; n=41) (p=0 ( p=00085 respectively). As plasma and urinary LTE4 conc may both reflect whole body pro cysteinyl leukotrienes, we attempte( plasma and urine LTE4 values in ea group. In the normals, logl0 plas and logl0 urine LTE4 were not sil correlated (r=-026, p=0 5; n=1 larly, in the asthmatic subjects, pl urine LTE4 concentrations correlato during the acute exacerbation (r p=0 9; n= 10) nor at follow up (r p=0-9; n=9). II error is of asthmatics must now be treated with caution. In our studies LTC4 and LTD4 were undetectable (<50 pg/ml) in all subjects, but LTE4 and LTB4 were detected in most normal and asthmatic subjects at concentrations results, a similar to those found by other workers was appar-using HPLC/radioimmunoassay techniques.3' Geometric However, venous plasma LTE4 was relatively tration was low and highly variable, and failed to fully 54) during reflect the significantly increased cysteinyl and 179 leukotriene production in the asthmatic at follow children that was observed in urinary LTE4 than in the concentrations. Moreover, plasma LTE4 con-97.7, 95% centrations did not correlate with urinary )025 and LTE4. This lack of sensitivity suggests that plasma LTE4 measurements may not be useful entrations as an adjunct to LTE4 urinalysis. Suction of LTE4 concentrations in urine are used as a d to relate marker of whole body production of cysteinyl ch subject leukotrienes because a fixed proportion ,ma LTE4 (4-6%) of 3H-LTC4 infused intravenously in gnificantly man emerges as 3H-LTE4 in the urine within 14). Simi-four hours, irrespective of the dose adminislasma and tered.32 Several studies have described an ed neither *=-0-061, = -0053, luction of in urinary tly higher not only but also a eturned to ;e potent asthma is related to lay rather ?rocess in bronchial we have f the proded to be the acute . Remission Normal exacerbation (n = 9) children (n = 10) (n = 41) Figure 3 Concentrations ofLTE4 (log scale) in the urine of asthmatic patients during acute exacerbation and in remission, and in normal children. Horizontal bars indicate geometric mean and 95% CI; dotted line indicates detection limit of the assay. Urinary LTE4 concentrations were significantly higher in the asthmatics both acutely (p=0 003) and in remission (p=O OO9) compared with the normals. 
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increase in urinary LTE4 in susceptible asthmatic adults after challenge with allergen, 6 33 34 exercise,7 and aspirin. 35 Relatively few studies have examined urinary LTE4 excretion in relation to the variable lung function of clinical asthma. Taylor and colleagues found increased urinary LTE4 in 20 adult asthmatics admitted to hospital for an acute exacerbation.6 Only eight of these asthmatics were re-examined at follow up, and in these subjects urinary LTE4 concentrations had not fallen significantly, despite systemic corticosteroid and theophylline treatment resulting in a return to normal lung function. Increased urinary LTE4 has also been found in a significant proportion of stable adult asthmatics.33 In our study, urinary LTE4 concentrations were approximately double normal values both acutely and in remission in asthmatic children suggesting chronic overproduction of the cysteinyl leukotrienes.
There is overwhelming evidence for chronic inflammation in the bronchial mucosa even in mild asthma. Our work supports the concept that cysteinyl leukotrienes may have a role in the chronic inflammation in the bronchial mucosa in asthma, and that this may underlie the early indications of an anti-inflammatory and steroid sparing effect of cysteinyl leukotriene receptor antagonists in current clinical trials. The possibility of an involvement also of LTB4 in chronic asthma in children strengthens the case for the further development of 5-lipoxygenase inhibitors which may counteract the actions of both classes of leukotriene. Further studies are called for to investigate the effects of 5-lipoxygenase inhibitors on leukotriene production in long term studies in health and disease.
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APS is supported by the Frances and Augustus Newman Foundation, and DPC by the Royal Air Force. We thank Dr R Sherwood (Department of Clinical Biochemistry, King's College Hospital) for performing creatinine analyses, Dr A W Ford-Hutchinson (Merck-Frosst Canada) for the kind gift of LTB4 antiserum, and Professor B Peskar (University of Graz, Austrna) for generously donating the cysteinyl leukotriene antiserum.
